STOCKS TELEGRAPH

Tag: CVM

  • CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) stock prices were up by 5.20% as of the market closing on June 25th, 2021, bringing the price per share up to USD$25.08 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.42%, bringing it up to USD$26.94.

    Bought Deal

    June 11th, 2021 saw the company announce its entering into an underwriting agreement with Kingswood Capital Market. As per the agreement, the underwriter made a purchase of 1.4 million shares of CVM’s common stock. Each share was priced at USD$22.62, with gross proceeds amounting to USD$31.7 million before the deduction of expenses related to the offering. The agreement also included a 30-day option for underwriters to purchase up to an addition 210,000 shares to cover over-allotments.

    MultikineTrial

    December 2020 saw the company’s Phase 3 head and neck cancer study complete database lock and enter the statistical analysis phase. Independent contractors have been hired to conduct the analysis process so as to ensure CVM stays blind to the study data. The company hopes to meet FDA safety and efficacy requirements, with the statistical analysis plan following the protocol states objectives. Furthermore, the company is keen to compile the clinical benefits the Multikine has the potential to provide patients that are newly diagnose, but not yet treated, for advanced primary squamous cell carcinoma of the head and neck.

    Multikine Production Facility

    With the commercial launch of Multikine looming closer, CVM has been allocating resources towards the expansion and upgrading of its proprietary cGMP manufacturing facility for Multikine. Construction began in 2020, with completion anticipated for the next several months. Upon completion, the company plans to double the facility’s capacity to accommodate two shifts for maximum production of Multikine.

    Financial Reports

    The six month period ended March 2021 saw the company report an operating loss of USD$17.3 million, up from the USD$13.6 million reported for the six month period ended March 31st, 2020. Operating loss for the quarter ended March 31st, 2021 was USD$8.5 million, up from the USD$6.7 million reported for the same time period of the prior year. The six and three-month periods ended March 31st, 2021, respectively reported USD$6.9 million and USD$3.3 million in capitalized costs.

    Future Outlook for CVM

    Armed with the nearing commercialization of Multikine, CVM is poised to continue its trajectory of success by allocating resources towards Multikine’s proliferation in the U.S and global markets. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    In the current trading session, CEL-SCI Corporation (CVM) stock surged by 20.45% to the price of $24.15 at the time of writing. CVM stock closed Wednesday’s session at $20.05 which is a gain. The stock volume traded today for 6.17 million shares. The shares exchanged hands five times the average volume of trade for the past 3 months. For the past year, CVM stock soared by 75.42%, and the past week it had also jumped 19.42%. In the past three and six months, the stock has gained 38.75%and 33.67% respectively. Furthermore, CEL-SCI is currently valued in the market at $766.11 million and has 40.53 million outstanding shares.

    Biotech Investors are hinging on the success of Multikine phase 3

    CEL-SCI stock rallied up to 45% this week. The boost is coming due to the gathering of results for the advancement in the phase III trial of its flagship investigational product Multikine.

    On similar news related to Multikine, the company had seen a whopping gain of 82% in the month of January (on 26th) which was correlated with the WallStreetBets rally. Multikine is the only late-stage candidate of CVM stock and the reason behind the surge was the tweet by Geert Kersten – CEO of CEL-SCI which hyped up news about Multikine Phase III data’s release.

    However, the news of the release of data had dragged on even passing the month of February, in which the Kerstentold the investors to keep their head high for the data and have confidence in the stock. Now the hype is aired around the full data analysis readout for the clinical study of immunotherapy. Success of this lead investigative product will lead to a life-changing course of action for patients with squamous cell carcinoma in the head or the neck.

    Where will the success of Multikline lead the company?

    The success of phase III Multikline will move the company to a phase where it can commercialize this treatment and boost the value of the CVM stock. Furthermore, the company will become an attractive buyout candidate for big pharma companies waiting to gain the benefits of its future potential.

    CES-SCI’s lead product offering and operational background

    CEL-SCI Corporation is a biotechnology company that specifically focuses on the design and development of novel treatments that are offered to target the demands and unmet needs of patients with certain diseases. The biotech company aims to develop immunotherapies for the treatment of infectious diseases as well as cancer. The leading investigational immunotherapy of CEL-SCI is Multikine. Multikine is being developed for the treatment of head and neck cancer. The immunotherapy is currently under clinical phase III trial.

    CEL-SCI has also created a T-cell modulation procedure that can trigger the immune system to fight bacterial, parasitic and viral infections. The process is done by the system known as LEAPS which stands for Ligand Epitope Antigen Presentation System. LEAPS also focuses on the countering of autoimmune diseases, cancer, and allergies. The company uses this LEAPS system for a different platform which includes the treatment of rheumatoid arthritis and even a product candidate for coronavirus.